Andrew Barbour MBBS, PhD, FRACS

Dr. Andrew Barbour is a Surgical Oncologist the University of Queensland with a research interest in the treatment of cancer. His academic interests have encompassed the areas of 1) clinical research, including randomised controlled clinical trials, 2) laboratory based research, including molecular biology pertinent to upper gastrointestinal disease, pancreatic cancer and melanoma, 3) translational research integrating the laboratory and clinical domains.

As a surgeon, A/Prof Barbour specializes in the treatment of oesophageal, gastric, pancreatic and adrenal diseases, as well as melanoma and soft tissue tumours. He has expertise in minimally invasive treatments these conditions, including thoracoscopic/laparoscopic oesophagectomy and laparoscopic gastrectomy.

As a clinical researcher, A/Prof Barbour has been active in the conduct of clinical trials at Phase I, II and III levels. He is the Principal Investigator for multicentre phase II trials in oesophageal and pancreatic cancer, funded by the NH&MRC. Both of these national trials include biological substudies with tumour tissue and blood banking and subsequent molecular analyses aimed at answering specific questions, including the identification of biomarkers of response to therapy.

A/Prof Barbour is a translational researcher at the School of Medicine, The University of Queensland. He is the head of Surgical Oncology Lab at the School of Medicine. His research has focused on using genomic, epigenomic, mRNA expression and next generation sequencing data to classify oesophageal adenocarcinoma (OAC) and identify biomarkers of outcome. In addition, his lab is seeking to identify biomarkers for recurrence following surgery for stage III melanoma and contributes to the Australian pancreatic cancer genome initiative.